Glucotrack (Nasdaq:GCTK) announced today that it plans to expand its glucose monitoring technology to measure glucose in the epidural space.

Rutherford, New Jersey-based Glucotrack said CGM taking readings in the spinal epidural space could integrate with existing treatments for painful diabetic neuropathy (PDN). Specifically, Glucotrack sees spinal cord stimulation (SCS) technology as a potential integration candidate.

SCS devices feature electrodes placed in the epidural space, sending low levels of electricity directly into the spinal cord to relieve pain. Glucotrack’s sensor could work with existing SCS devices to measure glucose in PDN patients undergoing SCS treatment. The company says this combination could provide several advantages, including simplifying device management.

Get the full story at our sister site, Drug Delivery Business News.